Prescription Vigabatrin Powder Recalled for Defective Container Leakage Risk
InvaGen Pharmaceuticals recalls Vigabatrin for Oral Solution nationwide due to defective containers that may leak. Consumers with affected lot should contact their pharmacy or healthcare provider.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class I drug recall, which per regulatory guidance cannot be scored below Severe (4). The defect involves containers that may leak, risking incomplete dosing and product loss or contamination.
Plain-English summary
InvaGen Pharmaceuticals, a subsidiary of Cipla Ltd., is recalling Vigabatrin for Oral Solution, USP 500 mg per packet, due to defective containers. The powder packets may leak, potentially resulting in loss of medication or exposure of the product to contamination.
The affected product is limited to Lot #NB301030 with an expiration date of 03/31/2025. Approximately 1,240 boxes were distributed nationwide within the United States under NDC 69097-964-53.
Vigabatrin is a prescription anti-epileptic medication used to treat seizures. A defective container that allows powder to leak may prevent patients from receiving their full prescribed dose, potentially affecting treatment effectiveness. Additionally, leaked powder may become contaminated or degraded if exposed to air or moisture.
Consumers who have the affected product should contact their pharmacy or healthcare provider for guidance. The product should not be used.
The recalled product
- Product
- VIGABATRIN (VIGABATRIN)
- Brand
- VIGABATRIN
- Manufacturer
- InvaGen Pharmaceuticals, Inc.
- Category
- Drug
- Hazard
- defective-container
- medication-loss
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: NB301030
- Exp. Date 03/31/2025
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- SevereCIMZIA injection recalled due to lack of sterility assurance
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModerateVitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid
FDA (Drugs) · 2026-05-27